ABCG2 and neoplasm: As intra-tumor heterogeneity in PpIX fluorescence is known to contribute to heterogeneous PDT response in clinic25, our results suggest the use of ABCG2 inhibitors to enhance PDT outcomes by decreasing the heterogeneity in PDT response.